000304997 001__ 304997
000304997 005__ 20251118090749.0
000304997 0247_ $$2doi$$a10.1016/j.canlet.2025.218068
000304997 0247_ $$2pmid$$apmid:41016679
000304997 0247_ $$2ISSN$$a0304-3835
000304997 0247_ $$2ISSN$$a1872-7980
000304997 037__ $$aDKFZ-2025-01988
000304997 041__ $$aEnglish
000304997 082__ $$a570
000304997 1001_ $$aMills, Taylor S$$b0
000304997 245__ $$aMRC2 expression modulates metabolism in acute myeloid leukemia stem cells.
000304997 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2025
000304997 3367_ $$2DRIVER$$aarticle
000304997 3367_ $$2DataCite$$aOutput Types/Journal article
000304997 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1763453227_1939190
000304997 3367_ $$2BibTeX$$aARTICLE
000304997 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304997 3367_ $$00$$2EndNote$$aJournal Article
000304997 500__ $$aVolume 635, 28 December 2025, 218068
000304997 520__ $$aLeukemic stem cells (LSC) are well recognized for their essential roles in acute myeloid leukemia (AML) initiation and relapse. LSC can be distinguished from non-LSC AML cells by the expression of specific cell surface markers, but there is considerable phenotypic heterogeneity among LSC in AML. Here, using primary patient samples, we report that mannose receptor C-type 2 (MRC2) can be used to enrich for LSC across various AML subtypes. When compared to MRC2- AML cells isolated from the same patient samples, MRC2+ leukemic subpopulations show increased in vitro clonogenic capacity, a stemness transcriptomic signature, and enhanced leukemic capacity in mouse xenograft models. Further, we find that MRC2 is functional on AML cells, and enables their robust uptake of collagen, which supports their glycolytic metabolism. In sum these data highlight the use of functional surface markers to distinguish LSC in AML, and how they can yield insight into their unique characteristics.
000304997 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000304997 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304997 650_7 $$2Other$$aMRC2
000304997 650_7 $$2Other$$aacute myeloid leukemia
000304997 650_7 $$2Other$$aglycolysis
000304997 650_7 $$2Other$$aleukemia stem cells
000304997 650_7 $$2Other$$amannose receptor c-type2
000304997 650_7 $$2Other$$ametabolism
000304997 7001_ $$aArnone, Marlon$$b1
000304997 7001_ $$aGörsch, Elsa$$b2
000304997 7001_ $$aPoeschel, Simone$$b3
000304997 7001_ $$aWinter, Stefan$$b4
000304997 7001_ $$aKuebler, Jessica$$b5
000304997 7001_ $$aKimmich, Lucca M$$b6
000304997 7001_ $$aBüttner, Florian A$$b7
000304997 7001_ $$aWeller, Jan$$b8
000304997 7001_ $$aRudat, Saskia S$$b9
000304997 7001_ $$aMix, Lucas$$b10
000304997 7001_ $$aSchroeder, Jan C$$b11
000304997 7001_ $$aPaczulla Stanger, Anna M$$b12
000304997 7001_ $$0P:(DE-He78)0321c153233e619c095d93d9d5546c9d$$aSchwab, Matthias$$b13
000304997 7001_ $$0P:(DE-HGF)0$$aLengerke, Claudia$$b14
000304997 773__ $$0PERI:(DE-600)2004212-7$$a10.1016/j.canlet.2025.218068$$gp. 218068 -$$p218068$$tCancer letters$$v635$$x0304-3835$$y2025
000304997 909CO $$ooai:inrepo02.dkfz.de:304997$$pVDB
000304997 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0321c153233e619c095d93d9d5546c9d$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000304997 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000304997 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000304997 9141_ $$y2025
000304997 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-16$$wger
000304997 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER LETT : 2022$$d2024-12-16
000304997 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-16
000304997 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-16
000304997 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-16
000304997 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-16
000304997 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-16
000304997 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-16
000304997 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-16
000304997 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-16
000304997 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-16
000304997 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-16
000304997 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-16
000304997 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER LETT : 2022$$d2024-12-16
000304997 9201_ $$0I:(DE-He78)TU01-20160331$$kTU01$$lDKTK Koordinierungsstelle Tübingen$$x0
000304997 980__ $$ajournal
000304997 980__ $$aVDB
000304997 980__ $$aI:(DE-He78)TU01-20160331
000304997 980__ $$aUNRESTRICTED